Cystitis treatment with high dose chondroitin sulfate
View Patent ↗Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.
1. A method of treating cystitis in a subject, the method comprising treating the subject with a pharmaceutical composition comprising a unit dose of chondroitin sulfate in an amount from 350 mgs to 600 mgs, and an aqueous vehicle in a volume of from 10 mL to 100 mL, wherein the pharmaceutical composition is adapted for instillation to the bladder of a patient, so as to treat the cystitis in the subject.
2. The method according to claim 1 , wherein the chondroitin sulfate is present in an amount of 400 mg.
3. The method according to claim 1 , wherein the aqueous vehicle is present in an amount of 20 mL.
4. The method according to claim 1 , wherein the aqueous vehicle is phosphate buffered saline.
5. The method according to claim 1 , wherein the cystitis is interstitial cystitis.
6. The method according to claim 1 , wherein treating cystitis with the pharmaceutical composition comprises:
providing a subject afflicted with cystitis or a related condition, wherein a subject afflicted with a cystitis-related condition is identifiable as a subject that elicits one or more cystitis symptoms upon instillation of a potassium chloride solution; and
instilling the pharmaceutical composition into the bladder or urinary tract of the subject.
7. The method according to claim 6 , wherein the instilling is performed at least once weekly for a period of at least 6 weeks.
8. The method according to claim 6 , wherein the instilling is performed at least twice weekly for a period of at least 6 weeks.
9. The method according to claim 1 , wherein the pharmaceutical composition is essentially free from preservatives and other additives.
10. The method according to claim 1 , wherein the aqueous vehicle is present in a volume of from 10 mL to 40 mL.
11. The method according to claim 1 , wherein the pharmaceutical composition comprises a unit dose of 400 mgs of chondroitin sulfate in 20 mL of an aqueous vehicle.
12. The method according to claim 1 , wherein the pharmaceutical composition consists of a unit dose of 400 mgs of chondroitin sulfate and 20 mL of an aqueous vehicle.
13. The method according to claim 9 , wherein the pharmaceutical composition is contained within a vial.
14. The method according to claim 9 , wherein the pharmaceutical composition is pH 7.2, sterile, and contained within a vial.
15. The method according to claim 11 , wherein the pharmaceutical composition is essentially free from preservatives and other additives.
16. The method according to claim 1 , wherein the pharmaceutical composition is essentially free from preservatives and other additives, and comprises an aqueous vehicle present in a volume of from 10 mL to 40 mL.
17. The method according to claim 1 , wherein the chondroitin sulfate is present in an amount of from 375 mgs to 500 mgs.
18. The method according to claim 17 , wherein the aqueous vehicle is present in an amount of from 10 mL to 40 mL.
19. The method according to claim 18 , wherein the aqueous vehicle is phosphate buffered saline.
20. The method according to claim 18 , wherein the cystitis is interstitial cystitis.
21. A method of treating interstitial cystitis in a patient refractory to other forms of treatment, the method comprising administering to the patient by instillation a sterile pharmaceutical composition consisting of 400 mgs of chondroitin sulfate in a 20 mL aqueous vehicle, wherein the composition is administered twice weekly for 6 consecutive weeks.